Venus Remedies Limited Market Cap ($190.12 Million)

$190.12 Million USD  · Rs17.58 Billion INR  · Rank #16521

Market Cap & Net Worth: Venus Remedies Limited (VENUSREM)

Venus Remedies Limited market cap. Venus Remedies Limited (NSE:VENUSREM) has a market capitalization of $190.12 Million (Rs17.58 Billion) as of November 4, 2026. Listed on the NSE stock exchange, this India-based company holds position #16521 globally and #848 in its home market, demonstrating a -10.03% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Venus Remedies Limited's stock price Rs1315.20 by its total outstanding shares 13366988 (13.37 Million). Also see VENUSREM operating cash flow for how efficiently the company converts equity into cash flow.

Venus Remedies Limited Market Cap History (2015–2026)

Venus Remedies Limited market cap history from 2015 to 2026. Data shows growth from $18.48 Million to $190.12 Million (23.45% CAGR). Check Venus Remedies Limited (VENUSREM) share price today for real-time trading data and today's change.

Venus Remedies Limited Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Venus Remedies Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Venus Remedies Limited (VENUSREM) equity growth momentum to track how rapidly the company is growing its equity base year over year.

Latest Price to Sales (P/S) Ratio

0.02x

Venus Remedies Limited's market cap is 0.02 times its annual revenue

Industry average: 0.58x Lower than industry average

Latest Price to Earnings (P/E) Ratio

0.24x

Venus Remedies Limited's market cap is 0.24 times its annual earnings

Industry average: 13.51x Lower than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $13.96 Million $4.15 Billion $16.99 Million 0.00x 0.82x
2017 $14.82 Million $3.96 Billion $79.09 Million 0.00x 0.19x
2018 $6.25 Million $3.69 Billion -$306.92 Million 0.00x N/A
2019 $3.24 Million $3.17 Billion -$285.75 Million 0.00x N/A
2020 $21.71 Million $3.37 Billion -$99.99 Million 0.01x N/A
2021 $58.86 Million $5.48 Billion $617.65 Million 0.01x 0.10x
2022 $26.18 Million $5.99 Billion $407.24 Million 0.00x 0.06x
2023 $58.73 Million $5.56 Billion $265.70 Million 0.01x 0.22x
2024 $46.03 Million $5.91 Billion $284.91 Million 0.01x 0.16x
2025 $110.75 Million $6.48 Billion $453.20 Million 0.02x 0.24x

Competitor Companies of VENUSREM by Market Capitalization

Companies near Venus Remedies Limited in the global market cap rankings as of November 4, 2026. Also see VENUSREM current and non-current assets for a full breakdown of the balance sheet.

Key companies related to Venus Remedies Limited by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #509 globally with a market cap of $52.60 Billion USD.
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #534 globally with a market cap of $50.42 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #580 globally with a market cap of $46.03 Billion USD ( CN¥314.55 Billion CNY).
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#509 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#534 GALDERMA GROUP AG NYSE:GALDY $50.42 Billion $45.90
#580 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $46.03 Billion CN¥49.31
#618 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €18.50

Market Capitalization of Venus Remedies Limited (2015–2026)

Market capitalization of Venus Remedies Limited from 2015 to today. Between 2015 and today, Venus Remedies Limited's market cap moved from $18.48 Million to $ 190.12 Million, with a yearly change of 23.45%.

Year Market Cap Change (%)
2026 Rs190.12 Million +71.67%
2025 Rs110.75 Million +140.57%
2024 Rs46.03 Million -21.61%
2023 Rs58.73 Million +124.32%
2022 Rs26.18 Million -55.53%
2021 Rs58.86 Million +171.20%
2020 Rs21.71 Million +570.31%
2019 Rs3.24 Million -48.21%
2018 Rs6.25 Million -57.80%
2017 Rs14.82 Million +6.16%
2016 Rs13.96 Million -24.48%
2015 Rs18.48 Million --

End of Day Market Cap According to Different Sources

On Nov 4th, 2026 the market cap of Venus Remedies Limited was reported to be:

Source Market Cap
Yahoo Finance $190.12 Million USD
MoneyControl $190.12 Million USD
MarketWatch $190.12 Million USD
marketcap.company $190.12 Million USD
Reuters $190.12 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Venus Remedies Limited

NSE:VENUSREM India Drug Manufacturers - Specialty & Generic
Market Cap
$190.12 Million
Rs17.58 Billion INR
Market Cap Rank
#16521 Global
#848 in India
Share Price
Rs1315.20
Change (1 day)
+1.13%
52-Week Range
Rs441.75 - Rs1947.00
All Time High
Rs1947.00
About

Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormo… Read more